{"id":14099,"date":"2019-05-14T09:08:52","date_gmt":"2019-05-14T09:08:52","guid":{"rendered":"https:\/\/dejalex.com\/it\/2019\/05\/maxi-causa-di-cartello-negli-usa-nei-confronti-dellindustria-generica\/"},"modified":"2019-05-14T09:10:00","modified_gmt":"2019-05-14T09:10:00","slug":"maxi-causa-di-cartello-negli-usa-nei-confronti-dellindustria-generica","status":"publish","type":"post","link":"https:\/\/www.dejalex.com\/it\/2019\/05\/maxi-causa-di-cartello-negli-usa-nei-confronti-dellindustria-generica\/","title":{"rendered":"MAXI CAUSA DI CARTELLO NEGLI USA NEI CONFRONTI DELL\u2019INDUSTRIA GENERICA"},"content":{"rendered":"<p>In data 10 maggio 2019, 44 Stati degli Stati Uniti d\u2019America hanno intentato una causa dinanzi alla <em>Federal Court\u00a0<\/em>del <em>Connecticut\u00a0<\/em>nei confronti di venti imprese farmaceutiche, tra cui <em>Teva, Pfizer, Novartis<\/em>e <em>Mylan<\/em>, per aver posto in essere un cartello volto ad aumentare, e a mantenere artificialmente e coordinatamente elevati, i prezzi di oltre 100 farmaci generici, in alcuni casi superando il 1000%&#8230;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-2114 aligncenter\" src=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2019\/05\/Articolo_Maxi-causa-di-cartello-negli-USA-nei-confronti-dellindustria-g....jpg\" alt=\"\" width=\"557\" height=\"789\" \/><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2019\/05\/Articolo_Maxi-causa-di-cartello-negli-USA-nei-confronti-dellindustria-g....pdf\" target=\"_blank\" rel=\"noopener\"><i  class=\"x-icon x-icon-download\" data-x-icon-s=\"&#xf019;\" aria-hidden=\"true\"><\/i> Scarica l&#8217;articolo<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[x_icon type=\"tag\"] Globally Minded, Societ\u00e0, Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences<\/p>\n","protected":false},"author":3,"featured_media":220,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[338,370,319,422,307,392],"tags":[],"class_list":["post-14099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-diritto-europeo-e-della-concorrenza","category-farmaceutico-e-life-sciences","category-globally-minded-it","category-pubblicazioni","category-roberto-jacchia-it","category-societa"],"_links":{"self":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/14099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/comments?post=14099"}],"version-history":[{"count":1,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/14099\/revisions"}],"predecessor-version":[{"id":14100,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/14099\/revisions\/14100"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media\/220"}],"wp:attachment":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media?parent=14099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/categories?post=14099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/tags?post=14099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}